Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zagotenemab in MCI due to AD or Mild to Moderate AD
NCT03019536Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of zagotenemab in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started Jan 2017; status: completed.
02
Drugs
zagotenemab
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT03019536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019536.